The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The safety and efficacy of peritransplantation ruxolitinib in patients with MF
Haris Ali, MD, City of Hope, Duarte, CA, discusses the safety and efficacy of peritransplantation ruxolitinib in patients with myelofibrosis (MF), highlighting the results from a pilot study which demonstrated that peritransplantation ruxolitinib is tolerable and reduces the risk of graft-versus-host disease (GvHD). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
